Long-Term Effectiveness and Safety of Isatuximab in Combination with Pomalidomide and Dexamethasone in a Japanese Patient with Refractory Multiple Myeloma and 1q21 Amplification: A Case Report
Introduction: In the ICARIA-MM trial, isatuximab plus pomalidomide-dexamethasone (Pd) significantly prolonged progression-free survival, compared with Pd alone, in patients with relapsed or refractory multiple myeloma (RRMM), including those with gain or amplification of chromosome 1...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2025-01-01
|
| Series: | Case Reports in Oncology |
| Online Access: | https://karger.com/article/doi/10.1159/000543347 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction:
In the ICARIA-MM trial, isatuximab plus pomalidomide-dexamethasone (Pd) significantly prolonged progression-free survival, compared with Pd alone, in patients with relapsed or refractory multiple myeloma (RRMM), including those with gain or amplification of chromosome 1q, region 2, band 1 (1q21+).
Case Presentation:
We describe a 62-year-old Japanese man with 1q21+ RRMM, previously treated with three lines of therapy, who had a rapid and durable response to isatuximab-Pd. After the first isatuximab-Pd cycle, he had a complete response or better, which was maintained throughout 54 cycles (4.25 years). Isatuximab-Pd was generally well tolerated. The only serious adverse event was grade 3 cataracts.
Conclusion:
Our case shows that isatuximab-Pd is capable of inducing an enduring response in a patient with 1q21+ RRMM.
|
|---|---|
| ISSN: | 1662-6575 |